A chronic pain sponsor used Cytel's East Horizon to optimize interim analysis timing in an adaptive trial design.
Sponsors developing chronic pain therapies need to navigate complex trial design choices to reach patients without unnecessary delay. Cytel deployed East Horizon, its trial design platform, so the sponsor could evaluate a wider range of design characteristics and optimize the timing of interim analyses in an adaptive design. The page describes the benefit qualitatively and gives no figures.
Cytel is a biostatistics and clinical trial design firm whose East Horizon software is used by pharma sponsors for adaptive design, simulation and regulatory-ready statistical analysis
This sits in the Design & Stress-Test stage of the AI use-case lifecycle: Named examples from the tools pharma teams use to scope, prototype and benchmark an AI use case before committing to build it — data-catalog, sandbox and evaluation platforms.
Published by Cytel on its own site — read the original case study on cytel.com ↗
Note: Detailed results sit in a downloadable document that was not readable; the web page gives no figures.
Related use cases
- 01Cytel designed a Bayesian, externally controlled Phase III trial design that the FDA accepted for a novel anti-infection therapy.
- 02Cytel applied machine learning to find patient subgroups that benefit from treatment after a severe infection trial missed its primary endpoint.
- 03Novo Nordisk Transforms Clinical Trials With AI
- 04How Regeneron is discovering new treatments with AI
- 05How AI is changing drug discovery
- 06Bayer transforms global data management with Databricks